$531 Million is the total value of BVF INC/IL's 29 reported holdings in Q3 2016. The portfolio turnover from Q2 2016 to Q3 2016 was 120.0% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| CYTK | Buy | CYTOKINETICS INC | $45,873,000 | -3.1% | 4,997,071 | +0.2% | 8.64% | -14.3% |
| CLCD | New | COLUCID PHARMACEUTICALS INC | $29,120,000 | – | 763,300 | +100.0% | 5.49% | – |
| XENE | Buy | XENON PHARMACEUTICALS INC | $25,182,000 | +139.6% | 3,108,905 | +75.1% | 4.74% | +111.9% |
| OMED | Buy | ONCOMED PHARMACEUTICALS INC | $20,711,000 | +25.6% | 1,812,005 | +35.3% | 3.90% | +11.1% |
| IMDZ | New | IMMUNE DESIGN CORP | $9,096,000 | – | 1,200,000 | +100.0% | 1.71% | – |
| PTGX | New | PROTAGONIST THERAPEUTICS INC | $7,924,000 | – | 375,000 | +100.0% | 1.49% | – |
| SNSS | New | SUNESIS PHARMACEUTICALS INC | $3,192,000 | – | 730,361 | +100.0% | 0.60% | – |
| New | OREXIGEN THERAPEUTICS INCnote 2.750%12/0 | $2,650,000 | – | 10,000,000 | +100.0% | 0.50% | – | |
| OREXQ | New | OREXIGEN THERAPEUTICS INC | $2,440,000 | – | 734,976 | +100.0% | 0.46% | – |
| PTIE | Buy | PAIN THERAPEUTICS INC | $2,278,000 | -51.6% | 2,278,552 | +6.0% | 0.43% | -57.2% |
| PIRS | Buy | PIERIS PHARMACEUTICALS INC | $1,858,000 | +377.6% | 1,016,593 | +321.2% | 0.35% | +321.7% |
Other managers
Other managers that, in addition to the filing manager(s), that filed the EDGAR filing(s):
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2016-11-14
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| XENON PHARMACEUTICALS INC | 36 | Q3 2023 | 4.7% |
| PIERIS PHARMACEUTICALS INC | 30 | Q3 2023 | 2.8% |
| CYTOKINETICS INC | 29 | Q4 2020 | 11.8% |
| INFINITY PHARMACEUTICALS INC | 29 | Q2 2023 | 4.3% |
| XOMA CORP DEL | 28 | Q3 2023 | 7.3% |
| ARQULE INC | 27 | Q4 2019 | 4.8% |
| CHEMOCENTRYX INC | 26 | Q3 2019 | 13.8% |
| CYTOMX THERAPEUTICS INC | 26 | Q3 2023 | 5.3% |
| CORVUS PHARMACEUTICALS INC | 26 | Q3 2023 | 2.3% |
| ARRAY BIOPHARMA INC | 25 | Q2 2019 | 14.5% |
View BVF INC/IL's complete holdings history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2024-02-14 |
| 4 | 2024-01-29 |
| 3 | 2024-01-26 |
| 4 | 2024-01-09 |
| 4 | 2023-12-20 |
| 4 | 2023-11-17 |
| 13F-HR | 2023-11-14 |
| 3 | 2023-11-13 |
| 3 | 2023-11-06 |
| 4 | 2023-11-06 |
View BVF INC/IL's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.